| Control | CIA | CIA + anti-TNF-α | |
---|---|---|---|---|
n | 26 | 28 | 16 | |
Female n (%) | 12 (46) | 15 (54) | 8 (50) | |
Body mass at baseline (g) | 393.7 ± 8.8 | 380.6 ± 8.0 | 382.5 ± 11.3 | |
Body mass at termination (g) | 451.7 ± 8.8 | 420.5 ± 8.0 | 400.0 ± 11.3* | |
SBP (mm Hg) DBP (mm Hg) | 128 ± 2 87 ± 2 | 130 ± 2 88 ± 1 | 132 ± 2 86 ± 2 | |
Circulating inflammatory marker concentrations | Â | |||
TNF-α (pg/ml) | 91.2 ± 5.0 | 159.9 ± 7.0* (1.75 fold)a | 146.2 ± 9.6* (1.59 fold) | |
IL-6 (pg/ml) | 16.0 ± 1.8 | 31.1 ± 2.0* (1.94 fold) | 27.9 ± 2.6* (1.75 fold) | |
CRP (ng/ml) | 0.09 ± 0.03 | 0.58 ± 0.04* (6.4 fold) | 0.43 ± 0.05*# (4.8 fold) | |
Left ventricular diastolic function measures | Â | |||
e′ (cm/s) | 4.52 ± 0.11 | 3.60 ± 0.09* | 3.50 ± 0.11* | |
e′/a′ | 1.44 ± 0.06 | 1.27 ± 0.07* | 1.04 ± 0.04* | |
E/e′ | 25.12 ± 1.25 | 31.61 ± 1.34* | 32.52 ± 1.55* |